June 16, 2026 · 12:31 AM
Healthcare & Health Industry Wire — Week of June 16, 2026
This week's US healthcare digest covers AI health-tech funding (Adaptive Innovations' $50M, Lassie's $35M a16z round), two major FDA pediatric milestones (first OTC kids' CGM, Tzield's accelerated approval for Stage 3 T1D), the 2026 Medicare Trustees' 2033 insolvency warning, Ascension's AMSURG close, Humana's $900M Gentiva divestiture, and a patient tip on pediatric prediabetes screening.
Adaptive Innovations' $50M raise, Ascension's AMSURG close, Medicare's 2033 deadline, and Dexcom's first OTC kids' CGM — this week had something pressing for every corner of the industry.
Health-tech funding and products
Digital health capital kept moving this week, with AI-native platforms dominating the term sheets.
Adaptive Innovations closed a $50 million Series A led by Felicis and Bain Capital Ventures to expand its AI-driven home health platform beyond Texas. The company says it has delivered over 100,000 home health visits since 2025 and partners with every major Texas hospital system; Optum Ventures also participated. 1
Lassie, an AI agent that handles insurance portal pulls, reimbursement reconciliation, and record updates for small medical practices, raised $35 million Series A led by Andreessen Horowitz. The startup currently supports 700 practices across 49 states and claims its system saves practices more than 250,000 hours of labor annually. 1
Novellia banked $18 million from Spark Capital and Khosla Ventures to scale its patient-powered real-world data platform. Novellia works directly with patients to compile and de-identify up to 20 years of longitudinal medical records, then sells structured datasets to pharma and biotech R&D teams. It launched a consumer-facing mobile app alongside the funding announcement. 2
Ilant Health closed $15 million Series A led by Cornucopian Capital for its value-based obesity treatment platform, which offers GLP-1 and non-GLP-1 pathways directly through employers and health plans. Early results show members averaging 15% weight loss. 1
Earlier in the month, Lassie was one of the prominent deals, while Prometheus—a biotech building "artificial general engineers"—secured $12 billion in a headline raise reported by STAT News (paywalled). 3
Loading stats card…
Pharma and device: FDA news
Two pediatric-focused clearances and an approval headlined an active week at the agency.
Dexcom Stelo cleared OTC for children. On June 12, the FDA cleared the first over-the-counter continuous glucose monitor (CGM) for children, extending the Dexcom Stelo Glucose Biosensor System to patients two years and older who do not use insulin. The FDA previously cleared Stelo OTC for adults in March 2024. The sensor lasts up to 15 days, reports glucose readings every 15 minutes to a paired smartphone app, and can be managed by a caregiver's device. The clearance relied partly on real-world evidence from existing iCGM use in both age groups. The device is not for people with problematic hypoglycemia and is not for dialysis patients. 4
Tzield approved for pediatric Stage 3 Type 1 Diabetes. On June 12, FDA granted accelerated approval to Tzield (teplizumab) for a new indication: delaying insulin-production decline in patients ages 8–17 newly diagnosed with Stage 3 type 1 diabetes (T1D). Tzield was already approved for Stage 2 T1D. The drug carries a boxed warning for viral reactivation (Epstein-Barr virus and cytomegalovirus). A post-approval study to verify clinical benefit is ongoing. 5
Other activity: The FDA also approved its first treatment for chronic Hepatitis Delta Virus (HDV) infection on May 22 6, and issued draft guidance June 2 to accelerate cell and gene therapies for patients. On June 9, the agency expanded approved sunscreen ingredients for the first time in 20 years.
Insurance and policy
The 2026 Medicare Trustees Report, released June 9, concluded that Medicare's Hospital Insurance (Part A) Trust Fund will be depleted in the second quarter of 2033—one quarter earlier than projected last year. 7
The headline figures are stark. Medicare expenditures are projected to rise from 3.9% of GDP in 2025 to 6.5% by 2050 under current law. Spending on skilled nursing facilities (SNF), home health, and hospice is projected to grow at 7.0%, 7.3%, and 8.9% annually over the next decade—faster than the 4.8% projected for inpatient hospital services. Medicare Advantage now covers 51% of beneficiaries, up from 50% in 2024, and is projected to reach 56% by 2035. 7
Loading chart…
To bring Part A revenues and expenditures into balance under current law, policymakers would have needed to either cut scheduled benefits by 12% starting in January 2026, or raise the Medicare payroll tax from 2.90% to 3.46%.
Separately, Dr. Oz—administrator of the Centers for Medicare & Medicaid Services (CMS)—outlined priorities at the Healthcare Financial Management Association (HFMA) annual conference this week, addressing Medicaid work requirements, prior authorization reform, and fraud reduction. 8
Hospital M&A
Consolidation has stayed active through mid-2026. Becker's Hospital Review tallied 18 hospital M&A transactions finalized so far this year. 9
The biggest deal to close this week: Ascension completed its acquisition of AMSURG, the ambulatory surgery center operator with approximately 300 locations. The deal, valued at roughly $3.9 billion, marks a deliberate pivot by the Catholic health system toward outpatient and ambulatory care. 10
Other notable closings from the Becker's tracker include:
- Lifepoint Health acquired eight community hospitals from ScionHealth across six states on June 2, extending its community hospital footprint. 9
- Freeman Health System (Missouri) paid $110 million for four Arkansas hospitals from Community Health Systems, marking CHS's exit from Arkansas. 9
- Humana announced an agreement to divest its minority stake in Gentiva, the nation's largest end-of-life care provider, valuing its interest at approximately $900 million. The deal is expected to close in Q3 2026 pending regulatory approval. Humana acquired the stake through its 2021 Kindred at Home purchase and has been shedding non-core assets since. 11
Patient health tip
Prediabetes affects millions of children — and a free tool can now help catch it early.
The FDA's clearance of the Dexcom Stelo CGM for kids as young as two underscores a growing concern: prediabetes is increasingly common in children, even those who aren't using insulin. The American Diabetes Association recommends that children ages 10 and up (or after puberty onset) with overweight and at least one additional risk factor—such as a family history of Type 2 diabetes, a diagnosis of high blood pressure, or a sedentary lifestyle—be screened for prediabetes. 4
The screening is a simple fasting blood glucose or A1C test ordered by a pediatrician. Catching prediabetes early—before it progresses—gives children and families the opportunity to reverse course through diet and exercise changes before medication becomes necessary.
What to ask at the next well-child visit: "Should my child be screened for prediabetes?"
References
- 1Fierce Healthcare Fundraising Tracker '26
- 2Novellia Series A press release
- 3STAT News — Prometheus raises $12 billion
- 4FDA press release — Stelo OTC CGM for children
- 5FDA press release — Tzield pediatric Stage 3 T1D
- 6FDA press announcements index
- 7Bipartisan Policy Center — 2026 Medicare Trustees Report
- 8Chief Healthcare Executive — Dr. Oz at HFMA 2026
- 9Becker's Hospital Review — 18 hospital M&As finalized in 2026
- 10Chief Healthcare Executive — Ascension acquires AMSURG
- 11Fierce Healthcare — Humana divests Gentiva stake
Add more perspectives or context around this Post.